|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquired_by
|
gptkb:Gilead_Sciences
gptkb:Abb_Vie
|
|
gptkbp:acquisition_year
|
gptkb:2020
|
|
gptkbp:business_model
|
research and development
|
|
gptkbp:ceo
|
gptkb:Dr._Behzad_Aghazadeh
gptkb:Dr._Christopher_D._Mc_Gowan
|
|
gptkbp:clinical_data
|
extensive research
|
|
gptkbp:clinical_expertise
|
oncology specialists
|
|
gptkbp:clinical_expertise_area
|
biopharmaceutical development
|
|
gptkbp:clinical_outcomes
|
improved patient outcomes
|
|
gptkbp:clinical_trial
|
ongoing
Phase 3
various cancer treatments
high success rates
positive outcomes
|
|
gptkbp:clinical_trials_phase_1
|
completed
|
|
gptkbp:clinical_trials_phase_2
|
ongoing
|
|
gptkbp:clinical_trials_phase_3
|
initiated
|
|
gptkbp:collaborations
|
with research institutions
|
|
gptkbp:collaborative_research
|
with academic institutions
|
|
gptkbp:community_involvement
|
philanthropic efforts
|
|
gptkbp:economic_development
|
sustained growth
|
|
gptkbp:employees
|
approximately 300
|
|
gptkbp:fda_approval
|
gptkb:2020
|
|
gptkbp:financial_performance
|
growing revenue
|
|
gptkbp:focus
|
oncology
|
|
gptkbp:founded
|
gptkb:1982
|
|
gptkbp:founder
|
gptkb:Dr._David_M._Goldenberg
|
|
gptkbp:funding
|
secured grants
|
|
gptkbp:future_plans
|
expansion of product line
|
|
gptkbp:global_presence
|
international operations
|
|
gptkbp:headcount
|
gptkb:300
|
|
gptkbp:headquarters
|
gptkb:Morris_Plains,_New_Jersey
gptkb:Morris_Plains,_NJ
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Immunomedics
|
|
gptkbp:invention
|
multiple granted patents
|
|
gptkbp:investment
|
various venture capital firms
active engagement
significant funding rounds
|
|
gptkbp:investor_confidence
|
high levels
|
|
gptkbp:market
|
consumer insights
|
|
gptkbp:market_cap
|
$21 billion (2020)
|
|
gptkbp:market_launch
|
successful
|
|
gptkbp:market_position
|
leading in oncology
|
|
gptkbp:marketing_strategy
|
expansion into new markets
|
|
gptkbp:notable_products
|
gptkb:Trodelvy
|
|
gptkbp:partnerships
|
pharmaceutical companies
various pharmaceutical companies
biopharmaceutical companies
|
|
gptkbp:partnerships_with_government
|
collaborative projects
|
|
gptkbp:pipeline_products
|
multiple candidates
|
|
gptkbp:product_development
|
innovative approaches
|
|
gptkbp:product_pipeline
|
diverse candidates
|
|
gptkbp:product_research
|
ongoing development
|
|
gptkbp:product_type
|
biopharmaceuticals
|
|
gptkbp:publication
|
numerous
|
|
gptkbp:regulatory_compliance
|
gptkb:various_countries
adherence to standards
|
|
gptkbp:research
|
leading studies
|
|
gptkbp:research_areas
|
gptkb:Oncology
antibody-drug conjugates
|
|
gptkbp:research_institutes
|
collaborations with universities
|
|
gptkbp:revenue
|
$100 million (2020)
|
|
gptkbp:scientific_innovation
|
cutting-edge research
|
|
gptkbp:social_responsibility
|
community initiatives
|
|
gptkbp:stock_symbol
|
IMMU
|
|
gptkbp:team
|
experienced executives
|
|
gptkbp:therapeutic_focus
|
targeted therapies
|
|
gptkbp:therapeutic_indications
|
various cancers
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:training
|
ongoing development programs
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.immunomedics.com
|
|
gptkbp:bfsParent
|
gptkb:Bristol-Myers_Squibb
gptkb:Gilead_Sciences
|
|
gptkbp:bfsLayer
|
4
|